1. Home
  2. MCRB vs ACOG Comparison

MCRB vs ACOG Comparison

Compare MCRB & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • ACOG
  • Stock Information
  • Founded
  • MCRB 2010
  • ACOG 2000
  • Country
  • MCRB United States
  • ACOG Canada
  • Employees
  • MCRB N/A
  • ACOG N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • ACOG
  • Sector
  • MCRB Health Care
  • ACOG
  • Exchange
  • MCRB Nasdaq
  • ACOG Nasdaq
  • Market Cap
  • MCRB 72.0M
  • ACOG 80.3M
  • IPO Year
  • MCRB 2015
  • ACOG N/A
  • Fundamental
  • Price
  • MCRB $7.05
  • ACOG $9.33
  • Analyst Decision
  • MCRB Hold
  • ACOG Strong Buy
  • Analyst Count
  • MCRB 5
  • ACOG 1
  • Target Price
  • MCRB $73.67
  • ACOG $20.00
  • AVG Volume (30 Days)
  • MCRB 93.5K
  • ACOG 199.2K
  • Earning Date
  • MCRB 05-07-2025
  • ACOG 05-15-2025
  • Dividend Yield
  • MCRB N/A
  • ACOG N/A
  • EPS Growth
  • MCRB N/A
  • ACOG N/A
  • EPS
  • MCRB 8.98
  • ACOG N/A
  • Revenue
  • MCRB N/A
  • ACOG $2,928,654.00
  • Revenue This Year
  • MCRB N/A
  • ACOG N/A
  • Revenue Next Year
  • MCRB N/A
  • ACOG N/A
  • P/E Ratio
  • MCRB $0.84
  • ACOG N/A
  • Revenue Growth
  • MCRB N/A
  • ACOG N/A
  • 52 Week Low
  • MCRB $6.53
  • ACOG $3.75
  • 52 Week High
  • MCRB $30.60
  • ACOG $11.40
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 38.95
  • ACOG N/A
  • Support Level
  • MCRB $7.32
  • ACOG N/A
  • Resistance Level
  • MCRB $7.86
  • ACOG N/A
  • Average True Range (ATR)
  • MCRB 0.63
  • ACOG 0.00
  • MACD
  • MCRB 0.10
  • ACOG 0.00
  • Stochastic Oscillator
  • MCRB 28.89
  • ACOG 0.00

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: